Novavax NanoFlu and COVID-Influenza Combination Vaccine Development 2022

Novavax presents development updates on its investigational NanoFlu vaccine and COVID-19-influenza combination vaccine candidates. The presentation covers clinical trial timelines, regulatory pathways, and the company's vaccine development programs including NVX-CoV2373 and Omicron-specific vaccine efforts.